While Astra Zeneca is exiting neuroscience, Sanofi is moving away from consumer health. The French biopharma has just announced that it has sold a 50% controlling stake in its consumer health business, Opella for US $11.4bn.
One of its plans post-sale is to “explore external growth opportunities for bolt-on acquisitions.”
Sanofi has both neuroscience and rare disease divisions.
One area of interest for Sanofi in neuroscience is neuroprotective drug candidates that target CNS inflammatory milieu, including microglia and astrocytes, and that prevent irreversible damage to neurons and glia and enhance regeneration.
In rare disease, Sanofi states that it is interested in later stage opportunities that would benefit from the company’s global commercial experience and capabilities.
https://www.fiercepharma.com/pharma/sanofi-gaining-eu10b-sale-opella-expect-more-bolt-dealshttps://www.sanofi.com/en/partnering/partnering-focus-areas/rare-disease
(20min delay)